Literature DB >> 15239405

May-Hegglin anomaly developing myelodysplasia and acute myeloid leukemia.

Naohito Fujishima, Makoto Hirokawa, Hiroyasu Ishikawa, Masumi Fujishima, Masaaki Kume, Ikuo Miura, Ken-ichi Sawada.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15239405     DOI： 10.1532/ijh97.03177

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  What is the difference between May-Hegglin anomaly and Sebastian platelet syndrome?

Authors:  M Tsurusawa; S Mamiya
Journal:  Int J Hematol       Date:  2000-06       Impact factor: 2.490

2.  Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation.

Authors:  L E Toothaker; D A Gonzalez; N Tung; R S Lemons; M M Le Beau; M A Arnaout; L K Clayton; D G Tenen
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

3.  Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome.

Authors:  A Takami; H Asakura; S Nakao
Journal:  Ann Hematol       Date:  2001-12-08       Impact factor: 3.673

4.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.

Authors:  M J Kelley; W Jawien; T L Ortel; J F Korczak
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  [Vitamin K2 therapy for myelodysplastic syndrome].

Authors:  Yasunobu Abe; Koichiro Muta; Nobuhisa Hirase; Ilseung Choi; Takamitsu Matsushima; Keiichi Hara; Fumihiro Taguchi; Eiichi Suematsu; Keisuke Shibata; Naokuni Uike; Junji Nishimura; Hajime Nawata
Journal:  Rinsho Ketsueki       Date:  2002-02

7.  Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.

Authors:  Shinji Kunishima; Tadashi Matsushita; Tetsuhito Kojima; Masahiro Sako; Fumihiro Kimura; Eun-Kyeong Jo; Chikako Inoue; Tadashi Kamiya; Hidehiko Saito
Journal:  Lab Invest       Date:  2003-01       Impact factor: 5.662

8.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.

Authors:  M Seri; R Cusano; S Gangarossa; G Caridi; D Bordo; C Lo Nigro; G M Ghiggeri; R Ravazzolo; M Savino; M Del Vecchio; M d'Apolito; A Iolascon; L L Zelante; A Savoia; C L Balduini; P Noris; U Magrini; S Belletti; K E Heath; M Babcock; M J Glucksman; E Aliprandis; N Bizzaro; R J Desnick; J A Martignetti
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

9.  MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness.

Authors:  Marco Seri; Alessandro Pecci; Filomena Di Bari; Roberto Cusano; Maria Savino; Emanuele Panza; Alessandra Nigro; Patrizia Noris; Simone Gangarossa; Bianca Rocca; Paolo Gresele; Nicola Bizzaro; Paola Malatesta; Pasi A Koivisto; Ilaria Longo; Roberto Musso; Carmine Pecoraro; Achille Iolascon; Umberto Magrini; Juan Rodriguez Soriano; Alessandra Renieri; Gian Marco Ghiggeri; Roberto Ravazzolo; Carlo L Balduini; Anna Savoia
Journal:  Medicine (Baltimore)       Date:  2003-05       Impact factor: 1.889
  9 in total
  1 in total

1.  Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases.

Authors:  Hamilton C Tsang; James B Bussel; Susan Mathew; Yen-Chun Liu; Allison A Imahiyerobo; Attilio Orazi; Julia T Geyer
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.